Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Cantargia, Audiocast, Q1'25

By Inderes5/13/2025, 1:00 PM
Cantargia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Damian Marron
00:00 - 09:10

Many thanks and welcome, everybody, to today's interim report of our first quarter 2025. On this next slide, you see our safe harbor statement, which, of course, is primarily intended to make everyone aware that any forward-looking statements we make should be approached with caution and not relied upon as guarantees of future performance. So as we've just introduced, I'm Damian Marron, the interim Chief Executive Officer. I'll be taking the first few slides for you and then handing over to Morten Lind Jensen, our Chief Medical Officer. And, um, we also have Patrik Renblad, our Chief Financial Officer, who will take us through the financial section of today's presentation. So it's been a busy first quarter and, um, actually a busy few weeks since the end of that quarter as well. So just quickly, here are the significant events that occurred in the first quarter of 2025. I was appointed as the interim CEO following the resignation of Göran Forsberg, our long-standing prior CEO. We then presented promising phase one data from our CAN10 first multi-dose cohort, as well as feedback from the FDA on the clinical trials. We finished recruitment in the randomized phase two trial for the study in triple-negative breast cancer. Nadunolimab. And we enrolled the first patient in a new investigator-initiated study of nadunolimab in leukemia that is taking place in the US. And we published two abstracts on IL1RAP-ADC and on nadunolimab's potential to reduce chemotherapy-induced neuropathy. We announced they would be presented at the AACR, which has just taken place. Significant results since the reporting period include the appointment of Morten Lind Jensen as Chief Medical Officer, and he will be speaking with you today. Uh, we selected treatment-resistant atopic dermatitis as our second indication for CAN10 in the CAN10 phase two program. And Morten will talk to you more about that. And we have also just announced that pharmacokinetic modeling, which used data from both the single ascending dose groups and the full data from the first multiple dose cohort in our CAN10 phase one study, has confirmed our choice of every four-week dosing in phase two, which we see as potentially a significant competitive advantage. And we'll show you some of that data in a few minutes. So moving to focus, first of all, on CAN10 and on the data we've been announcing since the start of the year. So just to quickly remind people, this is the design of our phase one first-in-human study, our single ascending dose, multiple ascending dose study. We started with ten cohorts of healthy volunteers who received single doses of CAN10. Um, and in each cohort, we increased the dose. And each cohort had six subjects who received CAN10 and two who received placebo. That has been completed and finalized, as we've already reported. We then moved into the multiple ascending dose, um, healthy subject cohorts. And here we have two two-dose cohorts. Again, six received CAN10 and two were given a placebo. And these dose cohorts will allow us to move into phase two. Um, so we anticipate finishing this study in Q2 and being able to start phase two towards the end of Q4 of this year. We also have some psoriasis subjects that we are studying separately, um, which will enable us to look to undertake some exploratory, mechanistic studies. And what we've shown to date is full receptor occupancy on immune cells. I'll show you that in a second. Uh, full blocking of IL-1 family cytokines. And very importantly, we have seen no safety concerns in either the single ascending dose or the completed multiple ascending dose cohort. So what have we seen as results? As I mentioned there, we have documented full receptor occupancy in the study. And you can see on the bottom left here for two different immune cell types: classical monocytes and neutrophils, that as we increase the dose in the single ascending dose. Part of the study, we reached full receptor occupancy on both of those cell types. And you can see on the right-hand side that we also achieve full receptor occupancy with the multiple ascending dose 14 days after the last dose was taken. So this is very encouraging data for us. On the right, you see an inhibition assay in whole blood taken from the subjects. And here on the right, you are looking at the ability of IL-36, one of the IL-1 superfamily that we block, to induce IL-6 release. And this is either at day one with the SAD or day 40 with the multiple ascending dose, and on the right-hand side, day eight on the single ascending dose. So eight days after that single dose, or again towards the end of the multiple ascending dose and treatment. And again, what you see here is that as we achieve full receptor occupancy, we also get full inhibition of IL-36. As we increase the SAD, or we look at the multiple ascending dose of 300 mg. You can see that we completely block IL-36. There is no more IL-6 release induced by applying IL-36 here. And if we go to the next slide, we also looked at the ability of IL-1 beta to induce IL-6 release. And again, we see a similar pattern where we can completely block the ability of IL-1 beta to induce IL-6 release, either after single doses or with the multiple ascending dose at 300 mg. This data is very important because it highlights the unique functions of CAN10 in blocking all of the IL-1 superfamily. So IL-1, IL-33, and IL-36. This is a unique function of an IL1RAP antibody like CAN10 and differentiates us from both approved treatments, but also treatments that are in development at the moment, such as the IL-1 alpha-beta blocker Lutikizumab, the IL-36 blocker Spesolimab, or indeed the IL-1 beta blocker that is in development by the US biotech company Arlo. And the importance of this is that we then make the immune cells non-responsive to IL-1 and IL-36, and these are the immune cells that migrate into the tissues and actually cause the damage that we see with hidradenitis suppurativa patients. Hidradenitis Suppurativa. Finally, I spoke just before about the fact that our data now supports that we can use every four-week dosing, or Q4W, as it is shortened to. We have seen excellent PK results. We have a linear PK profile, and we have a higher bioavailability of CAN10. And this model that we're showing here is being developed by Certara using the data from all the subjects in the study, both single ascending dose and multiple ascending dose. And the results from these simulations, as you can see, support the feasibility of Q4 weekly dosing. Along the bottom of the slide, you can see, at each four-week interval, that we have a 95% confidence. We do not have the drug level in the patient's blood dropping below what we call the C trough level, which is the lowest estimated level that we need for efficacy. So our combined results so far suggest we have great potential for efficacy. Um, we have good safety. We certainly have great convenience in its use for us and other future applications. And with this, I'll pass you over to Morten to take you through the next few slides.

Morten Lind Jensen
09:14 - 16:05

Yes. Hello. My name is Morten Lind Jensen and I'm the CMO at Cantargia. First of all, we have been looking at how to best utilize the very broad mode of action of this molecule? We know that the IL-1 family is broadly associated with both acute and chronic inflammation. And we know that there is a strong involvement of the multiple inflammatory cascades that we impact. And therefore, it also impacts multiple inflammatory diseases. So this broader mechanism where we both target inflammation and fibrotic elements is really something that can be used in many different indications. So we contracted with experts and explored where such a molecule could have relevance, identifying respiratory indications, indications with the bones and joints, indications in the gastrointestinal tract, and other systemic indications. And we did identify skin as one of the first indications for us to move into, with Hidradenitis suppurativa as the primary indication, but also atopic dermatitis, since it has such a broad involvement of both Th1 and Th2 inflammatory pathways, which has been identified as something that is highly relevant. And in particular, since we now know that Dupilumab is very broadly prescribed when there is a need for biologic treatment. However, there are people who don't benefit from Dupilumab, and of course, they should have an adequate treatment as well. Um, but in HS, our primary dermatological indication, the treatment landscape really looks like this for adalimumab. And there are the IL-17 blockers Bermekimab and Canakinumab. And those medicines are reasonably effective. They're administered every week or every other week. However, we believe that with this broader mode of action, a higher efficacy and less frequent dosing can be achieved. For the convenience of the patients and also for adherence to treatment. So we do want to look at the harder to achieve endpoints. We want to use HIscore 75 because it's more relevant for the patients compared to HIscore 50. It's really about looking at abscesses, inflammatory nodules, and tunnels in this disease. And it's super painful for them. So the pain of those lesions. This is what we want to aim for. And we believe that we can achieve higher efficacy with a less frequent dosing. So we really target the every second week dosing regimen in HS, and similar to when we looked at atopic dermatitis, it's clear that there is this very broad activation of the inflammatory pathways. In particular, when AD becomes more chronic, there seems to be a shift from the Th2 driven pathways towards Th1, Th22, and Th17, where it's also clear that Dupilumab is not relevant. It's IL-4 and IL-13. Right. So, our exploration of this indication really also looked at the indicators from other single cytokine monoclonals, where it looks like there is an effect, but it also looks like there is a requirement for a broader target of the inflammatory cascades. So the green boxes here indicate where there have been relevant individual cytokine studies and where we think there’s potential if we target more broadly, and targeting broadly is exactly what we do. So if we look at the non-clinical data we have and also the ex-vivo human data from the phase one study and from biopsies, it's clear that we do target multiple pathways. And we have both data from our animal peritonitis, animal cardiac inflammation, animal skin inflammation, and lung and skin fibrosis models. And we have the ex-vivo human whole blood study and the biopsies. And if we look at it cumulatively, all these pieces of information, it's clear that we target much broader. And we also target at different levels in the inflammatory cascade. So we have CAN10 that blocks IL-33 and IL-36, as we have talked about, and also IL-1 alpha and beta, as we have already discussed. But we also have in our heat maps clear indicators that we reduce IL-17. We reduce IL-5, we reduce the infiltration of monocytes, neutrophils, eosinophils, and T cells. We also reduce the activation and permeability of the endothelial cells. And we reduce the activation of mast cells. So, really, all these factors contribute to the broad inflammatory involvement in the disease, which leads to itchiness, scratching, and all the skin lesions. This molecule will indeed be effective even for patients who do not respond to Dupilumab. So, this is one of the other indications where this molecule holds great promise. And I think this was my last slide. Should I advance?

Damian Marron
16:05 - 28:18

That's great. No, thanks Morten. Thank you for that. Very clear run through of our approach to us and our newly chosen second indication there of AD. So I hope everybody has seen that the first quarter of this year and the subsequent few weeks have been really rich in data, strongly supporting the development of CAN10 in the serious skin conditions, as Morten has just explained with the rationale for both HSN and, obviously, the phase one single ascending, multiple ascending dose study has really produced all the data that we could have hoped for. Absolutely. To back up why we have pursued these indications, we can demonstrate that we can block these cytokines, block these immune cells, and we have great hope of delivering new levels of efficacy, safety, and convenience to patients with these inflammatory immune skin conditions. And then later, as Morten showed, we move on into other conditions as well. So that's where we will finish the focus on CAN10. And we will now move to talk about Nadunolimab, of course. Uh, or CAN10 for, um, our. Ah, the IL1RAP-ADC antibody that we've been developing in oncology for quite a long time now, but for which we have now developed substantial data, and we continue to move forward. In terms of the Nadunolimab clinical development, we have announced that we have the diagnostic test in development. This is a diagnostic test to identify patients who have different levels of IL1RAP-ADC in their tumors at the start of treatment. Um, what that will enable us to do is to select, as we go forward, or enrich, if you like, the studies that we are going to do, certainly in PDAC, pancreatic cancer, by selecting those patients who have a high IL1RAP-ADC level so we can treat that subgroup. And that is the subgroup, as I'm sure you will recall, which showed very encouraging overall survival data in our previous clinical studies. We'll move that forward. And we're planning for regulatory interactions during 2025. The development of this test does take some time. And so that will be the major activity in the PDAC program for 2025. Of course, PDAC is not the only indication that we have looked at with Nadunolimab. And indeed, we were very pleased to announce in March that we have completed the recruitment in what is our first randomized, controlled phase two study with Nadunolimab, the Triforce study in triple-negative breast cancer. The last patients are now under treatment, and we estimate to be able to release the initial results, which will focus on the overall response of the patients. After three months of treatment. We expect to be able to release that in mid-2025. So that's obviously going to be exciting news for the company at that point. And of course, separately, we have announced that we have recruited the first patient in a leukemia study in acute myeloid leukemia and in early myelodysplastic syndromes. This is a study that is taking place at The University of Texas MD Anderson Cancer Center and is sponsored by the US Department of Defense. This is a very interesting study in many ways because IL1RAP-ADC itself was first identified, actually, here at the University of London, as being present on leukemic precursor cells. So this is, in a way, a little bit of a full circle for the IL1RAP-ADC story and the development of Nadunolimab. Of course, we're not full circle because we still have a way to go before we can bring this treatment to patients. But this is a very exciting point in the development of Nadunolimab. Now we have treated over 300 patients overall, and we have, as you can see here, various oncology indications and opportunities for Nadunolimab to become a new treatment for patients who need these new oncology treatments, and to become a multi-million dollar product, developing value for our shareholders. We have also been presenting posters and having publications published around our Nadunolimab, mop-up work, and IL1RAP-ADC work. So we presented a very interesting poster just recently at the American Association of Cancer Research conference, linking clinical data with higher doses of Nadunolimab to a reduced incidence and a delayed onset of chemotherapy-induced neutropenia. Neuropathy, I beg your pardon? Chemotherapy-induced neuropathy, which is an exceedingly troublesome side effect of a number of chemotherapy regimens, often leads to patients discontinuing treatment or having to reduce their dose or prolong the interval between treatments. Overall, this means that patients are in poor health and are not receiving their optimal anti-cancer treatment. So this data is very interesting, and we backed this up with supporting preclinical data from mouse models looking at the mechanism of action, which indicate together that targeting IL1RAP-ADC nadunolimab not only has good anti-tumor activity as we've shown, but also can significantly reduce this chemotherapy-induced neuropathy. And actually, we've also shown that it can do this in the context of antibody-drug conjugates as well, which are also known to significantly induce neuropathy. So this is another very interesting set of data to support the development of Nadunolimab as we go forward. We also had a publication in Cancer Discovery by Hanahan et al. Followed up actually by a presentation by Professor Hanahan at AACR, where he highlighted the data, our preclinical and translational data, identifying the IL-1 family and its signaling as a key driver of cancer-related systemic immune suppression. And these findings really do provide strong support for us in our development of Nadunolimab and its potential to counteract tumor-driven immune suppression and therefore enhance its own activity, but also that of immunotherapy and potentially cancer vaccines also. So all in all, some very, very interesting and strong data around Nadunolimab has emerged since the start of this year. Finally, I want to say a few words to you about our next program. This is based on our library of over 200 IL1RAP-ADC antibodies, which we can tune to have different properties, and which offer us a number of pathways to value creation as we go forward. In particular, we have published data in a poster at the AACR about an anti-IL1RAP-ADC ADC. So IL1RAP-ADC is overexpressed in many tumors and also in the tumor microenvironment and in the stroma, around the supporting tissue, if you like, around the tumor and through the tumor. And what we were able to show was our anti IL1RAP-ADC ADC. An anti IL1RAP-ADC antibody is conjugated through a linker to a tumor-killing toxin, a toxin which cannot normally be delivered because it is too toxic for the body. But if you can make it locate in the tumor through a targeting mechanism, in this case IL1RAP-ADC, then you have very strong potential for treating the cancer. And what we were able to demonstrate was very strong tumor growth inhibition in tumor models expressing both high and relatively low levels of IL1RAP-ADC in their tumors. The ADC was also well tolerated in preclinical models, and we showed that adding the ADC function did not reduce the IL1RAP-ADC binding that we would look to see. So very exciting data in and of itself, but also illustrating the strength of this platform. Um, so we have, as I said, numerous antibodies with different properties that we can develop into new IL1RAP-ADC based therapies. So not just ADC, but we could look at bispecifics in oncology, but also in immunology. Um, alongside CAN10, we are looking to develop other antibodies targeting different indications. You saw the very large number of indications that the IL1RAP-ADC, the IL-1 superfamily, are implicated in, in immunology and autoimmune inflammatory diseases. And we could develop antibodies that are more suited for certain of those diseases than others, for instance. So not only do we have CAN10 and Nadunolimab, but now we also have, admittedly in early stages, the anti IL1RAP-ADC ADC and the possibility to continue developing other very interesting molecules as we move forward. Finally, from me, before handing over to Patrik Renblad to talk you through the financial figures, are our milestones for this year now. So we have already, um, in Q1, been able to publish the very exciting initial phase one data with CAN10 SAD and MAD. We have completed the recruitment for the Nadunolimab TRIFOUR study and we've started the investigator-initiated trial at MD Anderson in AML and MDS. As we move through the year for CAN10, we will fully complete the phase one study. Um, and later in the year we will look to file our IND, um, and subject to financing, start our study for PDAC. We will provide a regulatory update later in the year. Um, and obviously, as I said, around mid-year, we will aim to have initial results. Um, and then, uh, for CAN10 around the end of the year, we will have the phase two start in. And as I just mentioned. So we have an extensive news flow expected during 2025. And this can also be backed up with additional new preclinical and translational results, similar to the type that I've just shown you. So with that, I will hand over to Patrick to take you through our financial results. Thank you, Patrick.

Patrik Renblad
28:19 - 31:39

Thank you very much, Damian. And, uh, we announced this morning our financial report, which is the topic of why we are here today, for the first quarter of 2025. Um, and we started out with R&D expenses at about 46 million Swedish, which is slightly higher than we have been trending in the previous quarters, and it's 6% higher than Q1 last year. And that increase is driven by and reflects somewhat higher activity in the clinical programs for both CAN10 as well as Nadunolimab, but also due to our decision to produce more CAN10 antibodies, ensuring availability for the phase two programs. On the G&A side, we saw costs of four-plus million in the quarter. We have implemented relatively tight cost control. Um, but we saw an increase compared to the same period last year mainly due to organizational changes. So all in all, our operating loss was 45 million, and the reporting loss was 47 million. And the difference there reflects the impact of currency fluctuations, which negatively affects our currency hedging accounts. All in all, we also ended the quarter with a cash position of 104 million. We started at 33 million by the turn of the year. Um, we received $107 million in net proceeds from the rights issue that we conducted at the end of 2024. And we had a net outflow of 36 million, which consisted of 34 million in operating cash flow and 2 million in currency adjustments. And that kind of brought us to 104 million. Now, uh, we estimate that this, uh, will take us into Q4 this year in terms of our financial position. But, uh, we have flagged that it's not sufficient to fund operations throughout the entire year. We are actively working together with the board on various tracks and potential transactions to strengthen our financial position and ensure we are better funded. And with that, I hand over to you, Damien, for closing remarks.

Damian Marron
31:41 - 33:58

Thank you very much, Patrick. Yeah. So, um, so just in closing remarks, you know, it has obviously been a very active and very exciting first quarter and subsequent few weeks for the company. All of this is taking place against a macroeconomic and geopolitical background, which is exceedingly unfavorable for the whole biotech industry. Um, you know, I think anybody who is invested in biotech companies would be aware of that right now. Um, this doesn't make, um, you know, our job of creating value, um, any easier. But nevertheless, we are working exceedingly hard. We have a number of different tracks, ongoing business development, as Patrick referenced, including corporate transactions that we are exploring and other strategies to ensure we are in a position to finance the company and move it forward. Um, it's always a difficult area to talk about because we cannot give any details for, um, very obvious reasons of confidentiality. Um, with the parties with whom we're in discussion. Um, but, you know, we continue to move forward. Um, we remain as confident as we can be, uh, in the current circumstances. And of course, with no guarantees that we will be able to close a value-creating transaction for the company, and they are relatively, um, near term. And so, um, they are my, you know, final remarks for today, other than to thank you and to thank all of our shareholders for their support. Um, we don't take it lightly. Um, and, you know, we're all working very hard to create value for you, but also we're all motivated by the desire to develop new medicines for patients in serious need. And I think you can see that we're making strong progress on that as well. And that is how we will develop value for everybody. Um, so now, um, we can move across to Q&A. Um, it's always a difficult area to talk about because we cannot give any details for reasons of confidentiality.

Operator
34:00 - 34:22

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Luisa Morgado from Van Lanschot Kempen. Please go ahead.

Luisa Morgado
34:27 - 35:04

Hi, Tim. Thank you for taking my questions. Maybe to start out with CAN10, I was wondering, since you're now starting the cohort in healthy volunteers, and the one with injuries is in continuous recruitment. I was wondering, when will you share more data and if this will just happen throughout the first half of this year? And then also for CAN10, in terms of the pilot study in atopic dermatitis, could you provide any more details here regarding trial design, timelines, duration, and similar aspects?

Damian Marron
35:07 - 36:47

Thanks, Luisa, for your questions. Um, I'll take the first one and then I'll hand you over to Moulton to talk about, um, our initial ideas regarding what our study could look like. Um, but yes, our second, uh, multiple ascending dose cohort, um, is fully recruited, and is on the study right now and progressing. So we'll expect to be able to announce the data from that before the end of this quarter or around the end of this quarter. Um, psoriasis is a little more, um, difficult to predict. The enrollment of patients has been stop-and-go. Uh, or subjects, I should say. However, with these subjects who have psoriasis, the process has been stop-and-go. And to be quite honest, it's not been that easy. It's asking a lot of a person with psoriasis to take part in a study where they need to stay in a clinic overnight, undergoing skin biopsies and so on. Um, but we continue to move that forward and, um, are hopeful that we may get, uh, another subject or two, uh, into that shortly. Um, so I can't give you a time at this point when we can talk about the psoriasis data, but I would just remind you that it is not on our path to being able to file an IND and move to phase two. It really is exploratory, for mechanistic purposes. Um, so that's the, uh, the CAN10 Phase I. So, Morten, over to you about the AD study.

Morten Lind Jensen
36:50 - 39:11

Yes. Um, and the question about the AD pilot study, I think the question was about timing and trial design and so on. So, what is really important for us is to understand if this non-clinical mode of action, you could say clearly, translates into a clinical effect. And therefore, our first approach is a small pilot study. So, what we really aim to do is to expose. Around 30 patients with AD will be exposed for approximately 16 weeks, and then we will enrich the study with inadequate Dupilumab responders to clearly understand whether this translation holds true. And also the place we are at right now is that we have engaged with a handful of different CROs which are highly experienced within both psoriasis and atopic dermatitis, and we are currently interacting with them on the optimal study design. In recent years, atopic dermatitis has become increasingly difficult to recruit for and conduct good studies without being too impacted by the placebo response. It's critical to understand how we can collaborate with the CROs to ensure that we successfully deliver on this small pilot study while simultaneously executing the larger study. So what we really hope to be able to do is to start the recruitment or start the study at the end of this year, both in terms of the AD study, the small pilot study in AD, and the study.

Damian Marron
39:16 - 39:20

Thanks, Morten. I hope that answered your question, Louisa.

Luisa Morgado
39:20 - 39:57

Thank you. Yes. Very clear. Um, it's asking a lot of, uh, of a person with psoriasis to take part in a study where they need to be, um, staying in a clinic overnight, where they're having skin biopsies taken and so on. And nice to meet you, Morten. Maybe just one final question from my side, then. Um, in terms of what you mentioned, the regulatory interactions that you will have. That you are planning for this year for Nadunolimab. Um, could you just elaborate on what you expect to gather in terms of conclusions here? And this is not only relative to just the diagnostic tests, right. This is also just for the trial design of PDAC.

Damian Marron
40:00 - 40:55

Yeah. Initially, we are focused on discussions regarding the path to positioning the diagnostic so that it can support advanced phase two, stage phase three, or registrational type studies. That's very important. And make sure that we advance that in a way that will be acceptable to the regulatory agencies by the end of the year. And then, yes, of course, as we proceed, we would expect to have further discussions with the agency around the design. We've already had some in the past, some of which came back with answers relevant to Project Optimus, which have made us change our plans more than once as we've progressed. Um, so, yes, we'll be having those very important, um, discussions as well in due course.

Luisa Morgado
41:01 - 41:03

Okay. Thank you so much. That's all from my side.

Damian Marron
41:05 - 41:06

Thanks, Louisa.

Operator
41:09 - 41:13

The next question comes from Richard Romanus from Redeye. Please go ahead.

Richard Romanus
41:18 - 42:41

Good afternoon. I had some questions relating to the clinical study. The Phase 2 study of CAN10. So I guess that's for Morten. Could you provide more details about the design of this study? What line of patients are we using, refractory, or would you say patients who have undergone treatment before? Um, since I know. Sonelokimab for moonlight. They talked a lot about it there. I think it was a high score of 75, if I remember correctly, which was superior in their phase 2 study. So what relative performance would you expect? Um, and also, may I ask it straight away? Really? Um. There have been issues with these two studies not translating perfectly into phase three settings, and I think in psoriasis as well. Um, are you taking that into account in the design of the phase two study?

Morten Lind Jensen
42:45 - 46:01

And. Can I, or should I, start answering, please? Yes. Um, so, Richard, the thing about the high score is that it's sort of an artificial construct because the regulatory requirement, particularly from the FDA, is to use a high score of 50 in phase three studies. But what it really is, is that it's a reduction in inflammatory nodules and abscesses of more than 50% if its high score is 50 or more than 75% if its high score is 75, without an increase in either abscesses or fistulas. And um, the thing is that when we explore the efficacy, it's the delta between the placebo and the active that is important. And it is so in the different trials that it's harder to get a high placebo response in high score 75, because if you improve to a higher degree, then it really requires efficient treatment. So that's the rationale for selecting high score 75. It's really to see less of a placebo response. But in terms of interpretation, it's the delta between the placebo and the active arm that we would be looking for. And in terms of moving forward in phase three, at a later stage, we might have to switch to high score 50. But for phase two, the FDA has accepted high score 75 because it is essentially the same construct. And then about the translations, I think, yeah, you'd always be concerned about whether it translates correctly to the right effect when you expose the right patients. But I think the best thing we can do in this situation is to understand the disease. And this is something that really broadly involves inflammatory cascades. And then in the more progressed disease stages where you get a lot of tissue destruction, it gets even worse. So in my opinion, I think the broad mode of action is really what makes it super suitable for ACS. So I wouldn't be particularly concerned that we, um, don't translate successfully. And in particular, if we can administer the drug every four weeks, then I think we are at a good place with this molecule. And then, Richard, you had a third element, I think, but I forgot what that was.

Richard Romanus
46:02 - 46:07

Yeah. What line of treatment? Naive. Or if they're refractory.

Morten Lind Jensen
46:09 - 47:16

Yeah. So, we want to include both. And we have proposed that 30% will be treated with prior biologics, either TNF alpha or IL 17, and then 70% will be naive to ensure that in the phase two study, we collect data showing the effect both on those treated with prior biologics and those who are biologics naive. Oh yeah. And then your last question was about the expected level of. effect in the high score 75 of this drug. I would say that at least 40%. If we look at an expected placebo effect of 20. So we would have at least the following. Double the number of responders.

Richard Romanus
47:21 - 47:22

All right. Um.

Damian Marron
47:25 - 48:01

And if I could just add there, Richard, you know, our ambition. Sorry, Richard. I could just say our ambition, you know, clearly, is to achieve scores of 75 or higher, surpassing existing treatments. And we think that the mechanism of action we have, this broader mechanism of action, gives us every chance because we address more of the pathological processes than the single pathway blockers do. Um, so, yeah, you know, uh, that is the minimum that we expect to see, as Morten has just said. But our ambition is to be, uh, you know, certainly better than existing treatments.

Richard Romanus
48:06 - 48:25

Okay, so, um, let's see if you, if you achieve these results, how would that translate into, um, product placement? Um, I guess it would be difficult to get it in the second line in a case, or if you get a really great score, would that be possible?

Damian Marron
48:27 - 49:33

Uh, that's a really good question, Richard. You know, it crosses over into a whole number of subjects such as reimbursement, which is different in different countries, and pharmacy benefit management and hospital formularies and so on. But the general expectation is that, you know, many patients will first receive available treatments like generic biologics. Unless, Unless, um, you know, your data is absolutely incredible. Um, a lot of patients will, um, first of all, get, you know, generic biologics, um, such as TNF inhibitors, before they move on to, um, the newer, um, biologics afterwards. And that is simply a case of cost control. But the indication that we would go for would, um, obviously depending on the data. But given the population that we plan to use in phase two, if we use that in phase three, the indication would be to be able to treat both biologic naïve and refractory patients down the line.

Richard Romanus
49:39 - 50:09

So we would have at least the... the. Interesting. Um, let's see, I had some more questions pertaining to Nadunolimab. Uh, what? Phase two activities remain. Before you can, or let's say preparatory activities remain before you can start a phase two study, you mentioned you had produced enough substance. Are you conducting long-term toxicology studies or other activities?

Damian Marron
50:11 - 51:06

Yeah, there is a toxicology study which needs to be completed and reported out. And that's on the same timeframe as the phase one study. Um, so that is the other, um, key activity. Um, you know, and then as we continue to move forward, there will be, you know, continued, um, drug substance and drug product manufacturing. But in terms of the actual activities to get to the trial, it is getting the relevant amount of drug product in place to get underway and to ensure we can have continued continuity of supply. For the trial. It's to complete the phase one study and wrap up and report the toxicology study. That is a prerequisite. Yeah. Sorry, I asked for CAN10. Did you actually ask about Nadunolimab? Sorry.

Richard Romanus
51:10 - 51:36

Um, no. No, sorry. No, no. You're right. This was about, um. Yeah, this was about CAN10. Um, so that is the other, um, key activity. My mistake. But the right answer. Um, now, my question about Nadunolimab was, um. I misplaced my notes. My question about Nadunolimab was, um, when do you expect the result from the leukemia study?

Damian Marron
51:38 - 51:52

Um, well, you know, that's an investigator-initiated trial, so it is not under our direct control. Um, but we are expecting it is going to take around two years for that study to produce results.

Richard Romanus
52:00 - 52:05

Okay, thanks. That's all for my questions. All my questions.

Damian Marron
52:07 - 52:09

Um, so that is the other, um, key activity. Thank you, Richard. Appreciate it.

Operator
52:13 - 52:17

The next question comes from Sten Westerberg, an analyst. Please go ahead.

Sten Westerberg
52:22 - 53:25

Okay. Congratulations on a very productive quarter. Two questions on CAN10. First, can you explain the expansion of the phase one trial a bit more, considering it was originally estimated to enroll 80 patients and now is enrolling up to 116, which I think is a significant expansion for a phase one study? Is this entirely related to the ASC/MSC group, or have you made changes in the other groups as well? That's my first one. And also on the pharmacokinetics of the molecule. Will you have to give a loading dose of CAN10 in phase two, or will you directly move into a four-week dosing schedule? These are my two questions.

Damian Marron
53:25 - 54:20

Thank you, Sten, and thank you for your kind remarks at the start. Um, regarding the phase one study and its expansion, um, the enlargement was primarily undertaken to include single ascending dose groups so that we could escalate further. Increase in concentration or higher in dosing, I should say, because eventually, we want to have the highest therapeutic window we can and make sure that we deliver fully effective doses to patients. Um, so given how very good the tolerability was, we added, uh, more groups, um, to the study. I might ask Patrick, as he has more corporate memory than, uh, both Morten or myself, who are recent arrivals. If he has any extra details to add.

Patrik Renblad
54:20 - 54:53

No, I agree that's absolutely true. But we also added mid cohorts to, exactly as Damian said, explore higher doses. Um, and that's particularly because we, uh, we saw that in general, other competitors were actually dosing higher in TNBC than in other diseases. So, we wanted to have the freedom to give the right dose levels in phase two to patients in the NHS.

Damian Marron
54:57 - 55:14

Thanks, Patrick. Um, as you can hear, Stan, our chief financial officer has a much broader view of the company than many chief financial officers do. Um, absolutely. And, um, sorry, Stan, if you could remind me of your second question. The next question comes from Sten Westerberg, an analyst.

Sten Westerberg
55:15 - 55:28

The next question comes from Sten Westerberg, the analyst. Uh, it would be interesting to know if you will need a loading dose of CAN10 in future studies, or if you can move directly to the four-week dosing schedule.

Damian Marron
55:29 - 55:49

Yeah. To ensure that we get as quickly as possible to the steady-state pharmacokinetics, making sure that we're always above that c-trough level that I referred to. Uh, we will use one loading dose, um, at the start, um, of treatment in phase two.

Richard Romanus
55:54 - 55:54

Okay.

Sten Westerberg
55:54 - 55:56

One loading dose. Uh, we will use one loading dose, um, at the start, um, of treatment in phase two.

Damian Marron
55:56 - 56:07

Yeah. So to be clear, that would mean patients would receive an initial dose, followed by a dose at two weeks, and then another dose at four weeks. And then afterwards, every dose would be administered every four weeks as part of a quarterly schedule. Yeah.

Sten Westerberg
56:12 - 56:21

Okay. Understood. Uh, we will use one loading dose, um, at the start, um, of treatment in phase two. Um, so I understand there will be a loading phase in the study.

Damian Marron
56:22 - 56:25

Yeah. Yes, exactly. One loading dose. Uh, we will use one loading dose, um, at the start, um, of treatment in phase two.

Sten Westerberg
56:25 - 56:59

So in this. Um, in the, in the ADC field where there appears to be a lot of activities from all parties involved in, in oncology drug development. Can you provide us with any additional future plans or directions for your own preclinical programs? Will you be able to come up with a clinical development plan anytime soon, or what are your plans in this interesting field?

Damian Marron
57:01 - 57:49

At the moment, we're in the very early stages. Um, you know, we have just done this early work that we've just published. So, you know, we're some time away from designating a clinical candidate, and then moving forward into pre-IND studies. So, um, you know, but on the other hand, um, you know, the program has attracted some attention. You may also be aware that Pfizer published an IL1RAP-ADC poster at the same time as we did our paper. So you can see that, you know, there is industry interest in this area, and we would be very happy, you know, to collaborate with somebody around this, for sure.

Sten Westerberg
57:56 - 57:58

Okay. Uh, we will use one loading dose, um, at the start, um, of treatment in phase two. That concludes my questions.

Damian Marron
57:59 - 58:00

Thank you. Stan.

Operator
58:03 - 58:10

No more questions at this time. So, I hand the conference back to the speakers for any written questions or closing comments.

Unknown 1
58:11 - 58:19

Yes. The first written question is, how does the blocking of IL-1 beta relate to the blocking of IL-1 alpha?

Damian Marron
58:23 - 58:25

Morten. Do you want to take that one?

Morten Lind Jensen
58:28 - 58:45

Yes, but perhaps I'm not sure if we can show the slides again. There is one that really explains it quite well. Slide number eight. And. Now. Well, anyway.

Patrik Renblad
58:45 - 58:48

If it's showing there now. Yeah.

Morten Lind Jensen
58:49 - 59:37

Oh, yeah. It is. Stan. Cool. Yeah. So obviously, our non-clinical team and the CMC guys are much better at explaining the science of this. But if you look at the small yellow thing in the middle of the two parts of the IL-1 receptor complex, as well as 33 and 36, then placing it there blocks both IL-1 alpha and beta. So, you could say, how does it relate? It relates in this way that it blocks both IL-1 beta and IL-1 alpha.

Damian Marron
59:40 - 60:04

Yeah, exactly. Morten. And also, you know, as you said briefly, it blocks the IL-33 and all of the IL-36 isoforms as well. The only reason we don't have data is that there isn't a whole blood ex-vivo inhibition assay for IL-1 alpha, and that's why we haven't actually got data that we can show you. Um, but that is the way mechanistically that this works.

Unknown 1
60:07 - 60:14

Thank you. And the last question is related to the CAN10 program. How will you finance the next phase for that program?

Damian Marron
60:18 - 60:57

As we, as I hope I discussed earlier, you know, we are looking, and Patrick discussed this as well. We're looking at a whole range of ways of getting financing into the company, principally through business development and corporate transactions. Um, but we are also looking at all other options as well. It's quite clear at the moment that we can't finance it. Um, but we, um, you know, we remain as confident as I mentioned, as confident as we can be given the current circumstances and with no guarantees that we will be able to close the transaction that will allow us to move our programs forward.

Unknown 1
60:59 - 61:03

Thank you. And that was all the questions coming in from the web.

Damian Marron
61:05 - 61:35

And the last question is related to the CAN10 program. Jonas. Um, so on behalf of Patrick, Morten, and myself, I'd like to thank everybody, um, who's dialed in and listened today. Um, and we thank you very much indeed for your interest and your support. And we hope to repay that to you as soon as we can. Thank you very much.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…